120099-60-7

Basic information

• Product Name: (R)-3-METHOXYPYRROLIDINE
• Synonyms: (3R)-3-METHOXYPYRROLIDINE;(R)-3-METHOXYPYRROLIDINE;R-3MEHP;Pyrrolidine, 3-methoxy-, (3R)-
• CAS NO: 120099-60-7
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.15
• Mol File: 120099-60-7.mol

Chemical Properties

• Boiling Point: 123℃
• Flash Point: 35℃
• Appearance: /
• Density: 0.94
• Vapor Pressure: 13.6mmHg at 25°C
• Refractive Index: 1.445
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.49±0.10(Predicted)
• CAS DataBase Reference: (R)-3-METHOXYPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-METHOXYPYRROLIDINE(120099-60-7)
• EPA Substance Registry System: (R)-3-METHOXYPYRROLIDINE(120099-60-7)

Safety Data

• Hazardous Substances Data: 120099-60-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-Methoxypyrrolidine is used as a key intermediate in the synthesis of spiroindane-based imides, which are selective melanocortin 4 receptor (MC4R) agonists. These agonists are crucial for the development of novel therapeutics aimed at treating obesity by modulating the MC4R pathway, which plays a significant role in regulating energy balance and appetite.

InChI:InChI=1/C5H11NO/c1-7-5-2-3-6-4-5/h5-6H,2-4H2,1H3/t5-/m1/s1

Upstream product

• 672293-26-4 1-benzyl-3-(R)-methoxy-pyrrolidine 
• 74-88-4 methyl iodide 
• 549532-08-3 3R-methoxypyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1243675-28-6 C₃₈H₅₀ClF₂N₃O₃ 
• 1360551-08-1 2-[4-(3-{(R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-[1,2,4]oxadiazol-5-yl)pyrazol-1-yl]-((R)-3-methoxypyrrolidin-1-yl)ethanone 

Relevant articles and documents

4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME

An object of the present invention is to provide a compound or a salt thereof having anti-HBV activity, a pharmaceutical composition, an anti-hepatitis B virus agent, a production inhibitor of DNA of a hepatitis B virus, and a production or secretion inhibitor of a hepatitis B surface antigen. According to the present invention, provided are a compound represented by General Formula [1] or a salt thereof: (in the formula, R1 represents a benzothiazolyl group which may be substituted (in which a carbon atom constituting the 6-membered ring of the benzothiazolyl group of R1 is bonded to the nitrogen atom of the pyridone ring); R2 represents a C2-6 alkenyl group which may be substituted, or the like; and R3 represents a hydrogen atom or the like).

AMINOPYRIMIDINE HETEROCYCLIC COMPOUND WITH ADENOSINE RECEPTOR ANTAGONISTIC ACTIVITY

Disclosed hereinis an aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity, comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof. The aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activitydisclosed herein can be used as an effective adenosine receptor antagonist, and can be used for the treatment or prevention of disorders caused by abnormal level of adenosine.

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

3- Or 4-monosubstituted phenol derivatives useful as H3 ligands

The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Indole-type derivatives as inhibitors of p38 kinase

The invention is directed to methods to inhibit p38-α kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.